Glycine, serine and threonine metabolism confounds efficacy of complement-mediated killing

Zhi-xue Cheng1,2,7, Chang Guo1,7, Zhuang-gui Chen3,7, Tian-ci Yang4, Jian-ying Zhang5, Jie Wang1, Jia-xin Zhu3, Dan Li1, Tian-tuo Zhang3, Hui Li1,2,6, Bo Peng1,2,6 & Xuan-xian Peng1,2,6

Serum resistance is a poorly understood but common trait of some difficult-to-treat pathogenic strains of bacteria. Here, we report that glycine, serine and threonine catabolic pathway is down-regulated in serum-resistant *Escherichia coli*, whereas exogenous glycine reverts the serum resistance and effectively potentiates serum to eliminate clinically-relevant bacterial pathogens in vitro and in vivo. We find that exogenous glycine increases the formation of membrane attack complex on bacterial membrane through two previously unrecognized regulations: 1) glycine negatively and positively regulates metabolic flux to purine biosynthesis and Krebs cycle, respectively. 2) α-Ketoglutarate inhibits adenosine triphosphate synthase, which in together promote the formation of cAMP/CRP regulon to increase the expression of complement-binding proteins HtrE, NfrA, and YhcD. The results could lead to effective strategies for managing the infection with serum-resistant bacteria, an especially valuable approach for treating individuals with weak acquired immunity but a normal complement system.
The human complement system acts either independently or together with the immune system to kill bacteria in the bloodstream and/or on mucosal surfaces\textsuperscript{1,2}. However, a significant number of both Gram-negative and Gram-positive bacteria survive and proliferate in human blood that has a fully functional complement system. These pathogens are therefore referred to as serum-resistant bacteria, and they are associated with potentially serious systemic infections\textsuperscript{3–5}. Serum resistance has been extensively investigated, but the mechanism remains poorly understood at the molecular level. Most studies attribute the serum resistance of Gram-negative bacteria to bacterial outer membrane proteins, lipopolysaccharide (LPS) and its antibodies, and capsular polysaccharide in inhibiting complement system activation\textsuperscript{6–11}. Some outer membrane proteins bind complement-inhibiting factors, such as OmpA binding with C4b-binding protein, preventing the efficient formation of membrane attack complexes (MACs)\textsuperscript{12–15} while OmpC mutations increase bacterial survival in serum by inhibiting classical Clq and anti-OmpC antibody-dependent cell killing\textsuperscript{16}. The serum resistome of \textit{E. coli} K12 comprised of 56 genes, where a major proportion of the genes encode membrane proteins or factors involving in LPS biosynthesis\textsuperscript{17}. LPS is necessary for the survival of \textit{E. coli} in the blood\textsuperscript{18}. Immunoglobulin G to LPS confers serum resistance through shielding the bacteria from other antibodies that can induce complement-mediated killing\textsuperscript{10,19,20}. The presence of capsular polysaccharide is correlated with serum resistance in bacteria\textsuperscript{11}. Moreover, metabolism also plays roles in serum susceptibility, e.g., ferric uptake regulator (Fur) confers serum resistance\textsuperscript{21,22} and \(O_2\) consumption, adenine uptake, and glucose consumption increase are characteristic metabolic features when bacteria were exposed to serum\textsuperscript{23,24}.

These findings provide a clue to the molecular basis of serum resistance in Gram-negative bacteria\textsuperscript{6,10,18–22}. However, they do not provide insight into the metabolic state of serum-resistant bacteria, nor do they suggest promising strategies for managing infections with serum-resistant pathogens. To address this knowledge gap, our lab recently analyzed the metabolome of antibiotic-resistant bacteria. The results led us to propose that exogenous metabolite(s) might constitute a perturbation sufficient to restore antibiotic-sensitivity to multidrug-resistant bacteria\textsuperscript{25–29}. We also showed there is a link between bacterial serum resistance with metabolism\textsuperscript{29,30}. In the present study, we describe a framework based on functional metabolomics and metabolite perturbation, that might lead to a novel approach for controlling and/or preventing acute infection with serum-resistant and/or antibiotic-resistant pathogens.

Results

Glycine catabolism is reduced in serum-survival \textit{E. coli}. Comprehensive metabolomics provides information about the metabolic state of a cell or an organism, and how that state changes in different environmental contexts\textsuperscript{25,31}. We first showed that non-pathogenic \textit{E. coli} K12 was killed by serum but not by heat-inactivated (HI) serum and control without serum (Supplementary Fig. 1a, b). Then metabolome profiling was performed in these serum-treated bacteria as shown in (Supplementary Fig. 1c–e). In serum-survival \textit{E. coli} K12 cells, 59 metabolites were present at significantly different concentrations than the control without serum (\(p < 0.01\); Fig. 1a). Of the 59 metabolites, 44 were present at lower abundance in the presence of serum and 15 were present at higher abundance (Fig. 1b). A web-based metabolomics pathway analysis tool, MetPA, was used to evaluate the potential impact of differential metabolite abundance on metabolic pathways in the bacterial strain. This analysis identified 8 pathways differentially-expressed in \textit{E. coli} K12 in the presence of serum, with the largest predicted differential effect involving glycine, serine and threonine metabolism, with secondary and tertiary impact on alanine, aspartate and glutamate metabolism and the Krebs cycle (TCA cycle), respectively (Fig. 1c, d). Hierarchical clustering analysis identified glycine, serine, and threonine as three of the critically down-regulated metabolites (Fig. 1e; Supplementary Fig. 2), substantiating glycine, serine and threonine metabolism is the most significantly altered pathway in serum-survival \textit{E. coli} K12. The same analysis was performed for cells exposed to HI serum, displaying different signature and including increased glycine, serine, succinate, and fumarate (Supplementary Fig. 3).

qRT-PCR was used to demonstrate whether the reduced concentrations of glycine, serine, and threonine are linked to their catabolism or/and glycine transport. The expression of \(\text{glyA, kbl, sdaA, sdab, aceE, aceF,}\) and \(\text{glmA}\) mediating glycine flux to the TCA cycle was decreased, whereas \(\text{itaE}\) and \(\text{purD}\) mediating glycine to threonine and glycaminide ribonucleotide, respectively, was elevated when exposed to serum (Fig. 1f). Meanwhile, serum repressed the transcription of glycine transporter gene, \(\text{cyCA}\) (Fig. 1g). Thus, downregulation of glycine, serine and threonine catabolism to the TCA cycle is associated with active serum exposure, which is partly attributed to the decreased expression of glycine transporter. The further experiment demonstrated higher viability after re-exposure to serum (Fig. 1h).

Eight serum-resistant and eight serum-sensitive clinical isolates of \textit{E. coli} were selected (Supplementary Fig. 4). Their metabolic profiles also show a lower abundance of glycine, serine and threonine in serum-resistant strains than in serum-sensitive strains (Fig. 1i). Thus, it is possible that low abundance of glycine, serine, and/or threonine could serve as a biomarker of serum-resistance.

Glycine, serine, and threonine restore serum sensitivity. We hypothesized that uptake of an exogenous metabolite might perturb the metabolome of a serum-resistant bacterium and thereby restore sensitivity to killing by serum. To demonstrate this, exogenous glycine, serine, or threonine was added to a final concentration of 100 mM and cell viability was measured. The viability in the presence of serum was reduced by 85.0–6.8, or 8.9-fold, respectively (Fig. 2a). Exogenous glycine also significantly reduced viability of serum-susceptible strains \textit{E. coli} K12, Y5, and serum-resistant strains Y10, Y17 in the presence of serum, while no killing was observed in the controls (Supplementary Fig. 5a) and the effect was dependent on glycine dose (Fig. 2b), serum concentration (Fig. 2c), and time (Fig. 2d, e). When serum was treated by anti-C3, EDTA, or EGTA, glycine failed to potentiate serum to kill bacteria (Fig. 2f; Supplementary Fig. 5b). Survival of \textit{E. coli} Y17 was independent of the presence of serum during a 30-minute incubation, while under similar conditions, \textit{E. coli} K12 showed approximately 65% survival. However, in the presence of serum and glycine, Y17 cells lost viability over time, with less than 1% survival after 6 h (Fig. 2d, e). Exogenous glycine did not potentiate ampicillin or gentamicin to kill bacteria under the same condition to exclude the possibility that exogenous glycine impairs bacterial cell wall integrity as reported in Gram-positive bacteria\textsuperscript{32} (Supplementary Fig. 5c), even if the integrity is key to bacterial survival in the presence of antibiotics\textsuperscript{33}. In addition, sensitivity to serum was not restored by incubation in media containing various other amino acids and metabolites (Supplementary Fig. 5d). These data show that glycine, serine, or threonine specifically potentiates the ability of serum to kill strains of \textit{E. coli} that are otherwise resistant to such killing.

Effect of exogenous glycine on metabolic state. As suggested earlier, it is possible that serum-resistant could be reverted to
serum-susceptible based on the reprogramming metabolomes. To test this, glycine was selected as a metabolome-reprogramming metabolite. Therefore, metabolomic profiles of 73 metabolites were compared in E. coli K12, as described above (Fig. 1a–e; Supplementary Fig. 1c–e), using bacteria grown in media or in media plus glycine, serum, or both (Supplementary Figs. 6 and 7a–c). As compared to the control group, metabolites belonging to glycine, serine and threonine metabolism and to TCA cycle were lower in serum-exposed bacterial cells but increased when exposed to serum plus glycine except for threonine, which was decreased (Fig. 3a; Supplementary Figs. 7d and 7e). However, when serum plus glycine group was compared to...
Fig. 1 Serum-sensitive and -resistant bacteria have distinct metabolism. a Heat map showing relative abundance of 59 significantly differential metabolites in E. coli K12 in the absence (control) or presence (serum) of serum, as indicated. Heat map scale (blue to yellow, low to high abundance) is shown below data (n = 6). b Z-scores (standard deviation from average) corresponding to data in (a). c Pathway enrichment of significantly differential metabolites. Red box highlights the first three of most impacted pathways. d Pathway interconnections of the first three most impacted pathways. The change of metabolite abundance is indicated as follows: black, no change; red, upregulation; green, downregulation; gray, not detected. e Hierarchical clustering of the decreased abundance of metabolites in serum-treated samples. Heat map scale (gray to red; low to high loading) is shown below data. Red box highlights glycine and red dot highlights glycine, serine, and threonine metabolism. f, g qRT-PCR for the expression of glycine catabolism genes (f) and glycine transporter, cycA (g) in the presence or absence of 100 μM serum (n = 3). h Effect of repeated killing by serum on percent survival of E. coli K12. E. coli K12 was treated with serum (1) for selection of survivors, which was treated by the other two rounds of serum treatments (2 and 3). Percent of survival was calculated (n = 3). i Scatter plots showing a normalized abundance of glycine, serine, and threonine in eight serum-sensitive (Serum-S) and eight serum-resistant (Serum-R) clinical E. coli strains (n = 8). Results (g-i) are displayed as mean ± SEM, and significant differences are identified (*p < 0.05; **p < 0.01) as determined by two-tailed Student’s t-test. See also Supplementary Figs. 1-4.

Fig. 2 Glycine increases the susceptibility of E. coli to serum. a Percent survival of E. coli K12 incubated with 100 μL serum in the presence or absence of 100 mM glycine, serine, or threonine (n = 3). b Synergetic effects of 100 μL serum and glycine on viability of E. coli K12 were measured in a glycine dose-dependent manner (0-100 mM) (n = 3). c Percent survival of E. coli K12 incubated with 100 mM glycine plus serum (0-100 μL) or without glycine (n = 3). d, e Percent survival of E. coli K12 (d) and Y17 (e) in the presence of 100 mM glycine or/and 100 μL serum for the indicated length of time (n = 3). f Percent survival of E. coli K12 in the presence of 100 mM glycine or/and 100 μL serum or anti-C3 absorbed serum for 2 h (n = 3). Results are displayed as mean ± SEM (a-f), and significant differences are identified (*p < 0.05, **p < 0.01) as determined by two-tailed Student’s t-test (a-c, f). See also Supplementary Fig. 5.

glycine group, the abundance of glycine and threonine was reduced, while the abundance of succinate, fumarate, malate, and oxaloacetate in the TCA cycle was increased, suggesting serum drives glycine flux to the TCA cycle (Supplementary Fig. 8). Therefore, these results suggest that serum plus glycine triggers a metabolic change leading to increased production of NADH via the TCA cycle (Fig. 3b).

NADH would increase the membrane potential, thus potentiating cell death in the presence of serum plus glycine. In fact, we observed that exogenous glycine or serum correlates with an increase in membrane potential in E. coli K12 and Y17, with a synergetic effect of serum plus glycine relative to controls (Fig. 3c). The ionophore carbonylcyanide m-chlorophenyl hydrazone (CCCP) abolished the synergetic increase in membrane potential (Fig. 3c) and bacterial percent survival (Fig. 3d) in E. coli K12 or Y17 cells exposed to serum plus glycine. These results suggest that increased membrane potential is crucial for the synergetic effect of serum and glycine to revert serum resistance. Interestingly, membrane potential is significantly higher in E. coli K12 than Y17, and a differential synergetic effect of serum and glycine on membrane potential is found for the two bacterial strains (Fig. 3c). The results are consistent with the finding that E. coli K12 is more susceptible to the bactericidal activity of serum than Y17, and thus verifies the synergetic effect of serum plus glycine on survival.

With regard to the importance of membrane potential in serum-dependent cell death, it may relate to the recruitment of positively-charged C3 to the negatively-charged cell surface34–36. When membrane potential is sufficiently high, protons and/or electrons are transported across the membrane, which drives the synthesis of ATP, a reaction catalyzed by ATP synthase. Consistent with this, a defect in ATP synthase increases susceptibility to serum, which likely correlates with increased membrane potential (Fig. 3e; Supplementary Fig. 9).

We further validate the finding that exogenous glycine stimulates the TCA cycle using NTFD (non-targeted tracer fate detection)37,38 (Fig. 3f; Supplementary Tables 1 and 2). Furthermore, qRT-PCR showed that the expression of genes mediating glycine catabolism was increased (Fig. 3g). These results indicate that exogenous glycine stimulates the TCA cycle. Several other metabolites, including alanine, fructose, glucose, and glutamine stimulate the TCA cycle and increase membrane potential (Supplementary Fig. 10a)25–27; however, these metabolites did not decrease survival in the presence of serum.
Fig. 3 TCA cycle-triggered membrane depolarization. a Summary of metabolic flux through the TCA cycle in the presence of serum, serum plus glycine, or glycine. Change in metabolite abundance is indicated as follows: red, upregulation; green, down-regulation; gray, not detected. NADH concentration in E. coli K12 and Y17 treated with 100 μL serum, 100 mM glycine or both for 2 h (n = 3). b, c Membrane potential (c) and percent survival (d) of E. coli K12 and Y17 treated with 100 μL serum for 2 h in presence or absence of 100 mM glycine or/and CCCP (n = 3). For membrane potential, 50,000 cells were recorded with forward versus side scatter and were gated before data acquisition. d Percent survival of E. coli, ∆atpA, ∆atpC, and ∆atpD in the presence of 100 mM glycine, 100 μL serum, or both for 2 h (n = 3). e Mass isotopomer distributions for 13C labeled glycine detected in a nontargeted manner in the presence of 100 mM glycine, 100 μL serum for 2 h. f Percent survival of E. coli, ∆atpA, ∆atpC, and ∆atpD in the presence of 100 mM glycine, 100 μL serum, or both for 2 h (n = 3). g The relative flux for that metabolite in the TCA cycle (nTCA/nGly) is defined as (M2+M3+M4)/(M1+M2+M3) ratio, where nTCA refers to the turnover of a particular metabolite pool and nGly refers to the flux of glycine carbon atoms to the TCA cycle. g qRT-PCR for relative expression of genes contributed to the TCA cycle, and were gated before data acquisition.
(Supplementary Fig. 5d). This suggests that other factors may also be involved in addition to membrane potential.

**Glycine flux to the TCA cycle is essential for promoting the serum killing.** One possible explanation is that glycine promotes the expression of glycine-responsive genes, which in turn mediates the killing. To test this possibility, 12 *E. coli* K12 single deletion mutants of glycine metabolism were cultured in the presence or absence of glycine plus serum. Increased viability was observed in ΔglyA and Δkbl (Fig. 4a; Supplementary Fig. 9). These two genes encoded essential proteins to generate serine and threonine, respectively. Thus, these two proteins are required downstream of glycine to promote serum-dependent bacterial cell death, but they do not explain the mechanism of cell death.

Therefore, metabolic flux involving serine and threonine was explored. Genes that promote conversion of threonine to glycine were required for the killing effect, but others were not (Fig. 4b; Supplementary Fig. 9). However, loss of genes, sdaA, and sadB, transferring serine to pyruvate, abrogated the killing (Fig. 4c; Supplementary Fig. 9). Thus, these three metabolites must flux to pyruvate to play a role, although interregulation among them existed, which is supported by the fact that the absence of *itaE* decreased the effect of glycine, and lower viability was detected in ΔglyA than ΔtdcB and ΔiliV (Fig. 4a), suggesting it is required to flux threonine to glycine. Consistently, the viability of *E. coli* K12 cells was lower in the presence of serine than threonine at 6 h (Fig. 4d). When 50 mM serine or glycine was added, cell viability was equal at 6 h, but approximately four-fold fewer viable cells were detected than in the presence of the same concentration of threonine (Fig. 4e). We further demonstrated this through detection of glycine level in these mutants described in (Fig 4a). The glycine concentrations were proportional to the percent survival of the mutants (Fig. 4f), indicating that glycine flux to the TCA cycle is essential. We also showed that loss of *cycA* increased
cell viability (Fig. 4g). These results together support that glycine catabolism to the TCA cycle is critical to reverse serum resistance.

**α-Ketoglutarate regulates ATP synthase.** Following serine flux to the TCA cycle via pyruvate, we found gene-specific effects. In particular, the presence of genes in the pyruvate metabolism (aceE and aceF) and in the upper TCA cycle (gltA, acnA, acnB, icd, sucA, and sucB) induced rapid killing of bacteria by serum. In contrast, the presence of genes in the lower TCA cycle lacked this effect (Fig. 5a; Supplementary Fig. 9). These results were supported by the observation of increased serum-sensitivity in the presence of exogenous pyruvate, citrate, cis-aconitate, isocitrate or α-ketoglutarate, but not succinyl-CoA, succinate, fumarate, malate or oxaloacetate (Fig. 5b). To explain these results, we postulate that a defective step in the TCA cycle might lead to a defect in ATP synthesis. To explore this, ATP synthase activity was measured in the presence or absence of serine in *E. coli* K12, ΔaceE, ΔaceF, ΔgltA, ΔacnA, ΔacnB, and Δicd; these results show a significant effect in these mutants, but not other single deletion mutants tested here. The final gene in the pathway, icd, converts isocitrate to α-Ketoglutarate (Fig. 5c). Consistent with this, the amount of ATP was decreased in these strains (Fig. 5d). Glycerol and serine increased α-Ketoglutarate concentration in a dose-dependent manner (Fig. 5e) but not in Δicd cells (Fig. 5f). These results indicate that α-Ketoglutarate might inhibit ATP synthase. To further demonstrate this, microscale thermophoretic analysis (MST) showed that α-Ketoglutarate interacts with AtpB, a subunit of ATP synthase (Fig. 5g).

Exogenous glycine elevated intracellular α-Ketoglutarate in a dose-dependent manner, from 480 μM, a concentration reported previously, to 750, 110, 1300, and 1450 μM by 10, 20, 50, and 100 mM glycine, respectively (Fig. 5h), leading to 270–970 μM (1.56–3.20 folds) of α-Ketoglutarate increase. The inhibition of α-Ketoglutarate to ATP synthase appeared in 750 μM and 325 μM α-Ketoglutarate in cell lysis and purified AtpB, respectively (Fig. 5i). Clearly, exogenous glycine promoted the abundance of α-Ketoglutarate but inhibited ATP synthase activity in a dose-dependent manner (Fig. 5j). Thus, this accumulation induced by exogenous glycine is enough to inhibit ATP synthase.

---

**Fig. 5** The TCA cycle regulates bacterial serum susceptibility. **a** Summary of relative survival of the indicated mutant strains of *E. coli* K12 in the presence or absence of 50 mM serine plus 100 μM serum for 2 h (n = 3). **b** Summary of relative survival of *E. coli* K12 in the presence or absence of the indicated metabolites of the TCA cycle plus 100 μM serum for 2 h (n = 3). **c, d** Summary of relative ATP synthase activity (c) and ATP content (d) of the indicated mutant strains of *E. coli* K12 for 2 h in the presence and absence of 50 mM serine plus 100 μM serum. Heat map scale (a–d) (green to red) represents low to high killing (a, b) or ratio (c, d) without the indicated genes (a, c and d) or with the indicated metabolites (b) (n = 3). e, f Intracellular α-Ketoglutarate concentration in the presence or absence of 100 mM glycine or serine (e), and the effect of loss of icd (f) (n = 3). g AtpB and α-Ketoglutarate interaction assay by MST (n = 3). h Effect of exogenous glycine (0–100 mM) on the intracellular α-Ketoglutarate level (n = 3). i Measurement of intracellular ATP synthase activity using *E. coli* K12 cell lysis (cell lysis) or purified recombinant AtpB plus the indicated concentration of α-Ketoglutarate (n = 3). j The interrelation between α-Ketoglutarate level and intracellular ATP synthase activity from data (h, i) (n = 3). Results (e–j) are displayed as mean ± SEM, and significant differences are identified (*p < 0.05, **p < 0.01) as determined by two-tailed Student’s t test (e, h, i). See also Supplementary Fig. 9.
Exogenous glycine regulates purine metabolism. On the other hand, besides ATP synthase, ATP synthesis needs AMP and ADP. Therefore, a role for purine metabolism was explored, because mutations in purD, a gene involved in the de novo purine nucleotide biosynthesis, altered serum resistance (Fig. 4a), and reports have linked glycine metabolism with de novo purine synthesis.40,41 A series of mutant strains of E. coli K12, each deleted for a gene in the purine biosynthetic pathway, were cultured in the presence and absence of glycine plus serum. The results show decreased viability of most strains with defects in purine biosynthesis (Fig. 6a), suggesting that purine biosynthesis influences serum-dependent cell death. We validated this by demonstrating that ΔpurR cells, lacking a potent negative regulator of purine nucleotide metabolism, are more resistant to cell killing in the presence of serum and glycine than E. coli K12 (Fig. 6b; Supplementary Fig. 9). We supposed that this led to
deciding AMP level and thereby exogenous AMP and ATP might abolish the role of glycine. Consistent with the hypothesis, we detected a glycine-dependent decrease of AMP with time (Fig. 6c), and demonstrated that exogenous IMP, AMP, ADP, and ATP abolish glycine-dependent bacterial cell death (Fig. 6d). ATP analog had a similar effect as ATP (Fig. 6e). This finding suggests that ATP contributes to serum resistance.

PurR also negatively regulates glyA. We also show that loss of purR led to increased expression of glyA/GlyA and kbl/Kbl using qRT-PCR and Western blot (Fig. 6f, g). MST and electrophoretic mobility shift assay (EMSA) confirmed the binding of PurR with glyA and kbl (Fig. 6h–i). However, the results on the negative regulation do not explain why exogenous glycine, serine, and threonine flux to the TCA cycle rather than purine metabolism via PurD. One possibility is that these three metabolites positively regulate GlyA or/and Kbl but not PurD through substrate activation, which is over the action negatively regulated by PurR. To explore this, qRT-PCR was used to detect expression to glyA, kbl, and purD in E. coli K12 and ΔpurR cultured with different concentrations of glycine, serine, or threonine. High dose of these metabolites favored increasing glyA and kbl expression in E. coli K12. In details, the expression of glyA and kbl were elevated by glycine and threonine, and the expression of glyA was increased by serine, whereas no significant change was detected in the expression of purD in response to three metabolites (Fig. 6k). Consistent with the negative regulation of PurR to glyA and kbl, lower glyA and kbl expression was detected in E. coli K12 than ΔpurR (Fig. 6k). Western blot data also validated these findings, showing GlyA was increased in a dose-dependent manner, while the weak elevation of Kbl and no significant change of PurD were detected (Fig. 6l), and purD/PurD was not regulated by PurR (Fig. 6f, g). These results indicate that high dose of exogenous glycine leads to increased intracellular serine but lower purine biosynthesis; this may reflect the expression of elevated GlyA and unchanged PurD.

Mechanism of cell death in the presence of serum and glycine.

These above results suggest that ATP plays a role in the serum-mediated killing. To demonstrate this, we detected a glycine-dependent decrease of ATP over time lapse (Fig. 7a) and found that exogenous ATP abolished glycine-dependent bacterial cell death (Fig. 7b). We also found that intracellular ATP was positively regulated by exogenous ATP, ATPγS, ADP, AMP, but negatively regulated by serum, glycine/serum (Supplementary Fig. 10b).

ATP is converted into cyclic-AMP (cAMP) by adenylate cyclase (encoded by cyaA)33. cAMP and CRP (encoded by crp) form cAMP-CRP complex, a global transcriptional regulator controlling a minimum of 378 target promoters in E. coli34. Consistent with this, synergistic action of glycine and serum led to a decreased abundance of cAMP, whereas single glycine or serum did not affect cAMP level (Fig. 7c); loss of cyaA and crp led to decreased viability (Fig. 7d; Supplementary Fig. 9). We also demonstrated that the abundance of CRP increases in an ATP- and AMP-dependent manner (Fig. 7e), whereas CRP expression is downregulated by glycine (Fig. 7f). These results suggest that exogenous glycine may decrease the abundance of the cAMP-CRP complex in cells exposed to serum, which is supported by the fact that absence of fis increases viability in the presence of glycine since fis negatively regulates crp (Fig. 7d; Supplementary Fig. 9)45.

CRP positively and negatively regulates flhC and csgD, two genes that regulate fimbrial and pilus usher proteins, respectively46,47. HtrE and YhcD are fimbrial usher proteins and NfrA is a bacteriophage N4 receptor with similar molecular mass as usher proteins. CRP regulates expression of outer membrane proteins in the manner of FlhC and CsgD47. Consistent with this, loss of flhC and csgD led to upregulation and downregulation of NfrA, HtrE, and YhcD, respectively (Fig. 7g) and the respective percent survival (Fig. 7d). Moreover, the expression of nfrA/NfrA, htrE/HtrE, and yhcD/YhcD was higher in a crp-deleted mutant than in wild type control (Fig. 7g, h). The results suggest that CRP regulates expression of NfrA, HtrE, and YhcD in the manner of FlhC and CsgD. In addition, loss of ompA and ompC led to lower percent survival in the presence of serum but not in the presence of serum and glycine (Supplementary Fig. 11).

Flow cytometry analysis confirmed significantly lowest binding of anti-C9 neoantigen of the terminal complement complex (TCC, MAC, the whole C5b-9 complex) to the triple mutants, ΔnfrAΔyhcDCΔhtrE, ΔhtrEΔyhcDCΔnfrA, and ΔyhcDCΔhtrECΔnfrA, lower binding to the double mutants ΔnfrAΔyhcDCΔhtrE, ΔyhcDCΔhtrEC, and ΔhtrECΔyhcDC and low binding to the single mutants ΔnfrA, ΔhtrE, and ΔyhcDC as compared to control (Fig. 7i). Corresponding percent survival was detected in these mutants (Fig. 7i). These are consistent with the hypothesis that HtrE, NfrA, and YhcD could be the outer membrane proteins that promote binding of complement components in the presence of exogenous glycine.

Western blot analysis was then performed to measure relative expression of HtrE, NfrA, and YhcD in E. coli K12 grown in PBS, serum or in serum plus glycine. In the presence of both of serum and glycine, expression of HtrE, NfrA, and YhcD increased in a serum and glycine dose-dependent manner; in contrast, expression of HtrE, NfrA, and YhcD remained unchanged in the presence of media with added glycine, serum or saline (Fig. 7k, l). Similar results were obtained with E. coli Y17 and four pathogenic E. coli strains (Fig. 7m; Supplementary Fig. 12). These results indicate that glycine in the presence of serum stimulates expression of HtrE, NfrA, and YhcD.

To investigate whether the increased expression of HtrE, NfrA, and YhcD is contributing to the increased binding of components
of the complement system, flow cytometry was used. Serum or serum plus glycine led to the deposition of C3b and C5b-9 complex on the outer membrane of E. coli K12 and Y17 (Fig. 7n). In particular, anti-C3b/iC3b and anti-C9 neoantigen recognized intact C3b, its degraded product, iC3b, and a neoepitope of TCC on the surface of serum or serum plus glycine-exposed E. coli K12 and Y17, respectively. Furthermore, TCC was detected at higher abundance by flow cytometry, when cell killing was more efficient, such that more C3b/TCC was present on the surface of E. coli K12 and Y17 exposed to serum plus glycine than on the surface of control cells exposed to saline, glycine, or serum. Consistent with this observation, more C3b/TCC was present on the surface of E. coli K12 than on Y17 after exposure to serum or serum plus glycine (Fig. 7n). MST assay demonstrated that HtrE, NfrA, and YhcD were bound to C3 (Fig. 7o). Far-Western blot and co-immunoprecipitation also showed that HtrE, NfrA, and YhcD interact with C3b, but not with IgG control (Supplementary Fig. 13). Therefore, glycine potentiates killing of serum-resistant bacteria, possibly by upregulating HtrE, NfrA, and YhcD, enabling the complement-dependent MAC-mediated cell death.

In addition, we investigated effect of O-antigen on the glycine-mediated killing, which is critical for LPS-mediated serum resistance in E. coli. Among the 30 clinical E. coli strains, 27 strains were O-antigen positive (Supplementary Table 3). Waal works for LPS biosynthesis and is subjected to frequent mutations to generate serum resistance. The mutations of waal were detected in randomly selected E. coli, P. aeruginosa, and...
K. pneumonia strains (Supplementary Fig. 14). E. coli serotype O157:H7, with adhesive fimbrae and a cell wall that consists of an outer membrane containing LPS, was sensitive to the glycine-triggering killing (Supplementary Fig. 15a) while exogenous glycine did not affect waal transcription (Supplementary Fig. 15b). When waal was deleted, the glycine-mediated killing was either unaffected or reduced by 4.81–24.1% (Supplementary Fig. 15c). These results indicate that LPS is not the key target in the glycine-triggering serum killing.

**Loss of glyA confers serum resistance in serum-sensitive strains.** To validate this possibility at a physiological level, we constructed glyA single deletion mutants in two serum-sensitive strains Y3 and Y21 as Y3ΔglyA and Y21ΔglyA, respectively. Y3 and Y21 were more susceptible to serum than E. coli K12, but Y3ΔglyA and Y21ΔglyA were highly resistant to serum at a similar level of a serum-resistant strain Y15. When exogenous glycine was supplemented, percent survival was reduced in all the five strains. However, higher killing efficacy was detected in Y21, Y3, K12 than Y15, Y21ΔglyA, Y3ΔglyA (Fig. 8a). Correspondingly, glyA deletion resulted in increased glycine level in both Y3ΔglyA and Y21ΔglyA (Fig. 8b). However, the increased glycine level did not inhibit ATPase activity and ATP production (Fig. 8c, d) and thereby increased the cAMP level (Fig. 8e). These results indicate that serum-susceptible bacteria exhibit serum resistance when no glycine fluxes to the TCA cycle.

CRP is a transcriptional factor modulated by cAMP. We further explored whether loss of glyA would impact CRP activity. qRT-PCR and Western blot showed that the deletion increased CRP expression at both mRNA and protein level (Fig. 8f, g). CRP positively and negatively regulates FlhC and CsgD, respectively, which downregulate the expression of nfrA, htrE, and yhcD. Consistently, the deletion of glyA resulted in increased expression of flhC but decreased expression of csgD, nfrA, htrE, and yhcD (Fig. 8h). These results indicate that the elevated cAMP/CRP when glyA was depleted confers serum resistance through reducing NfrA, HtrE, and YhcD expression. Therefore, the metabolic flow of glycine to the TCA cycle is an essential step for sensitivity to serum-mediated killing.

**The potential is effective to serum-resistant pathogens.** To explore whether the glycine-mediated serum killing was applicable to a broad range of pathogens, more studies were performed on clinically-relevant multidrug-resistant E. coli, Klebsiella pneumonia, methicillin-resistant *Staphylococcus aureus* (MRSA), and *Pseudomonas aeruginosa*. These pathogenic bacteria were cultured in vitro in the absence or presence of serum or serum plus glycine. With the exception of a few E. coli strains and two strains of *P. aeruginosa*, all strains were serum-resistant. Cell death was 10- to 1430-fold greater in the presence of glycine and serum than in the presence of serum alone. The average (and range) of this effect was 143.97-fold (24.65–396.43) in E. coli, 67.08-fold (15.17–122.19) in *K. pneumoniae*, 49.28-fold (10.0–95.6) in *P. aeruginosa*, 45.08-fold (0.06–316.05) in *S. aureus*, and 27.8-fold (0.006–1280.8) in E. faecalis.
MRSA, and 230.41-fold (11.76–1430.83) in *P. aeruginosa* (Fig. 9a). Notably, MRSA is a Gram-positive bacterium deficient of outer membrane targeted by the MAC complex. Our results showed that higher level of C3 and C5 on the surface when glycine was supplemented (Supplementary Fig. 16), which requires further study.

A mouse model was used to explore the efficacy of glycine for inhibiting pathogenic infections in vivo. Glycine was delivered by intravenous injection at a dose of 10, 15, or 20 mg glycine/mouse twice a day for 2 days. BALB/c mice were infected with *E. coli* strains K12, Y1, and Y17, *K. pneumoniae* strains 1924 and 2125, MRSA strains 1 and 5, and *P. aeruginosa* strains 1 and 23.
via intraperitoneal injection. The results showed that bacterial load in the bloodstream, kidney, spleen, and liver of infected mice decreases in a glycine dose- and time-dependent manner (Fig. 9b, c, Supplementary Fig. 17). In the plasma, the concentration of glycine was increased dramatically and reached the plateau within 5 min after the first injection. Then the level was gradually decreased and was returned to the baseline after 1 h post-injection. A second injection was performed at 12 h after the first injection. A similar glycine change level was observed but with a bit of higher abundance (Supplementary Fig. 18). In contrast, the level of glycine was elevated in liver, kidney, and spleen in a dose-dependent manner at 48 h after the first injection (Fig. 9d). The glycine-enabled killing of bacteria by serum was detected in RagI−/− null mice which do not bear mature T cells or B cells, supporting the glycine-mediated potential is independent of immunity endowed by the mature T cells or B cells (Fig. 9e). To demonstrate the role of glycine and complement in the potentiation, BALB/c mice were injected with K12, ΔycA, or ΔnfrAΔyhcDAΔhtrE, respectively. Bacterial load in the bloodstream, spleen, and liver was higher in ΔycA-infected or ΔnfrAΔyhcDAΔhtrE than K12-infected mice (Fig. 9f), thereby validating that glycine, and HtrE, NfrA, YhcD play roles.

We also showed that E. coli K12 cells remained inviable in vitro in the presence of serum plus glycine after five serum-killing/dilution-culture cycles, while showing weak susceptibility to serum in the absence of glycine (Supplementary Fig. 19).

Survival of E. coli K12 and Y17 decreased significantly in media with glycine plus serum from mouse and pig, as did survival of V. alginolyticus in media with glycine plus fish and shrimp plasma (Fig. 9g). This result suggests that the metabolic pathways and the biological basis of serum-dependent cell death in the presence of exogenous glycine are similar in mammals and some non-mammalian species.

We further explored whether glycine potentiates antibiotics to eliminate serum-susceptible or serum-resistant and multidrug-resistant bacterial pathogens. Percent survival of E. coli was lower in glycine with ampicillin or kanamycin than only glycine or the drugs (Supplementary Fig. 20). Mice were infected with pathogenic E. coli Y9 (serum-resistant and multidrug-resistant), E. coli Y23 (serum-susceptible and multidrug-resistant), P. aeruginosa 22 (serum-resistant and multidrug-resistant) or K. pneumoniae 0367 (serum-resistant and multidrug-resistant). The synergistic use of glycine and ampicillin increases the survival rate of the infected mice. Specifically, mice infected with E. coli Y9 or E. coli Y23 had a 100% survival rate if both glycine and ampicillin were treated, and a 70% survival rate if only the glycine was treated, while the survival rate dropped to 0–10% if treated with ampicillin alone or with saline. Similarly, mice infected with P. aeruginosa 22 or K. pneumoniae 0367 had a survival rate of 70–80% when both of ampicillin and glycine were treated, and a 40–50% survival rate if only glycine was treated, while 10% survival was found if treated with ampicillin alone or with saline (Fig. 9h). These results indicate that glycine promotes ampicillin to kill serum-susceptible or serum-resistant and multidrug-resistant pathogens.

Discussion

Serum resistance as bacterial pathogenesis was found more than a hundred years, but information regarding effective controls is not available. The present study highlights the way to eliminate serum-resistant bacteria through metabolome-reprogramming. The core findings of this study are: (1) downregulation of glycine, serine and threonine catabolism to the TCA cycle and stimulates synthesis of NADH and increases membrane potential, which facilitates the binding of complement to the outer membrane. It is clear that metabolites dominate the novel demonstrated metabolic regulation pathways. Colors: pink, upregulation; grass green, down-regulation.
In the present study, two novel findings are interesting. First, a novel metabolic regulation pathway is disclosed. Glycine is con-
suc-tively transformed to α-Ketoglutarate and then α-Ketogluta-
rate interacts with ATP synthase. It is an interesting finding that bac-
terial α-Ketoglutarate inhibits ATP synthase, demonstrating a mecha-
ism to maintain membrane potential that involves metabolite feedback. Second, we suggest that metabolite feedback may override the effects of global gene regulation. More specifi-
cally, although PurR negatively regulates glyA and kbl, a high con-
centration of glycine, serine, or/and threonine increased concentration of glycine, serine, or/and threonine increased expres-
sion of glyA/GlyA and kbl/Kbl several-fold. In addition, the regula-
tion of PurR to kbl and glyA to crp/CRP is found. And HtrE, NfrA, and YhcD are unknown complement-binding outer membrane proteins.

Methods

Ethics statement. Animal protocols were approved by the University Committee for the Use and Care of Laboratory Animals. All work was conducted in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

Bacterial strains and growth conditions. In this study, the parent strain E. coli K12 BW25131 (genotype, Δ[ara/ara-3]/676, ΔlacZΔ78/cremB-3), lambda-, rpl-1, A(delA)fl, and its knockout strains were taken from the K. Bullock collection. A single colony of E. coli K12 BW25131 and its knockout strains were picked from the Luria-Bertani (LB) agar plate. Reliability of these mutants was validated by gene sequencing, which primers were listed in Supplementary Table 4. These bacteria were separately inoculated in 5 mL of LB medium for 16 h at 37 °C and spun at 2000 rpm. Overnight cultures were diluted 1:100 in 50 mL fresh LB medium and grew to phase OD600 of 0.3 at 37 °C. Bacterial cells were collected by centrifugation at 8000 × g for 10 min at 4 °C and suspended in saline solution. Unless otherwise noted, 100 mM glycine was added and cultured at 200 rpm for 2 h in 37 °C in all experiments. Samples were pre-treated with the proton ionophore FCCP for 5 min in all experiments. The other bacteria, multidrug-resistant E. coli, P. aeruginosa, K. pneumonia, methicillin-resistant Staphylococcus aureus (MRS), V. alginolyticus and V. para-hae-molyticus were from the collections of our labora-
tory. These cells were insensitive to at least three classes of antibiotics including β-lactamases, aminoglycoside, quinolones or/and sulfonamides. Unless otherwise noted, the culture conditions were the same above. All bacterial strains used were listed in Supplementary Table 5.

Serum killing. Human serum was collected from 200 healthy donors. The collected sera were packaged and kept at −80 °C for future use. Package sera were not used repeatedly when they were taken from the refrigerator. The collected bacteria above were suspended with sterile saline and adjusted to OD600 of 1.0. Aliquots 3 mL of the bacteria were added in a 5 mL centrifugation tube and were centrifuged at 8000 × g for 10 min in 4 °C. The remnants of normal saline were removed by pipette. Then, 100 mL serum, C3-depleted serum (puri-
fied by anti-human C3 antibody) and its knockout strains were taken from the K. Bullock collection. The sera were diluted with sterile saline, and 10 µL aliquots were spot-plated onto LB agar plates. The plates were cultured at 37 °C and the colony-forming unit (CFU) were cal-
culated the next day. Only those of dilutions yielding 200 colonies per sample. Plotted Z-scores were calculated based on the mean and standard deviation (control without serum, unless otherwise stated). Hierarchical clustering based on Pearson’s correlation was performed on the log-
transformed normalized data after median centering per metabolite. The multi-
variate statistical analysis included independent component analysis (ICA) (http://
metagenenalyse.mpimp-golm.mpg.de/). ICA was used to discriminate sample pat-
terns, to identify the metabolites associated with infection and to minimize the interaction of individual samples. Principal component analysis (PCA) was used to reduce the high dimension of the data set.

Metabolomic profiling. GC-MS analysis was carried out with a variation on the two-stage technique25. Peak intensities were normalized to form a single matrix in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

Measurement of NADH and cAMP concentration. NADH was measured with a commercial kit according to the manufacturer’s instruction (Cat. GMS00972, Beijing, China). Bacteria with 3 × 10^6 CFU were disrupted by sonica-
tion (20% output and 5 s interval time for a total of 3 min) in an ice-bath. For measurement of NADH, the samples were centrifuged at 12,000 × g for 10 min at 4 °C. Supernatants were collected and protein concentration was measured. A total of 0.3 µg of protein were used for NADH quantification. For measurement of cAMP, the samples were centrifuged at 12,000 × g for 5 min at 4 °C and 100 µL supernatant of each sample was used for measurement according to the manu-
facturer’s instructions (Cat. K371, CAMP Direct Immunoassay kit (Colorimetric, BioVision, USA).

Membrane potential. E. coli cells were adjusted to 1 × 10^6 cells/mL in saline, and with 10 µL of FCCP (3) for 30 min at 37 °C. One microliter of cultures was analyzed on a FACSCalibur (flow cytometry at 37 °C (Becton Dickinson, San Jose, CA, USA). Each sample was processed with forward scattering versus side scatter and was gated before data acquisition, record count: 50,000 cells. The fluorescence of DIOCC(3) was excited at 488 nm and emitted at 530 nm (green) or 610 nm (red). The green fluorescence is determined by size while the red fluorescence is determined by membrane potential. The ration of red to green indicated fluorescence intensity values of the gated populations. The computational formula of membrane potential = Log(10^0.2 x red fluorescence/green fluorescence)32.

Absolute ATP and α-Ketoglutarate levels and ATPase activity. Intracellular water content was measured as follows26. Bacterial cells were harvested in the OD600 of 1.0 by centrifugation at 12,000 × g for 10 min at 4 °C by centrifugation with sterile saline. Followed by measurement of the wet and dry weight of the cells, the intracellular water content (g) was calculated from the equation: 1–0.23 - D / W, where W is the wet weight and D is dry weight. The constant value is 0.23. To quantify intracellular ATP, α-Ketoglutarate concentrations and F type ATPase activity, dry cells from 10 mL of 1.0 OD600 were dissolved in 100 µL PBS buffer (pH 7.4) and disrupted by sonication (20% output and 5 s interval time for a total of 3 min) in an ice-bath. The solution was diluted 1:500 for measurement of ATP and α-Ketoglutarate concentrations and F type ATPase activity, with BacTiter-Glo® Microbial Cell Viability Assay (Cat. GR231, Promega, Madison, WI), α-Ketoglutaric Colorimetric/Fluorometric Assay Kit (Cat. K677, BioVision, USA) and F-type ATPase Activity Assay Kit (Cat. GMS02482, Genmed, Shanghai, China), respectively. The intracellular concentrations and enzyme activity unit were quantified according to the manufacturer’s manual and intracellular water content26.

Western blot, far-Western blot, and Co-IP. Western blot, far-Western blot, and Co-IP were performed as follows27–29. For Western blot, samples were dissolved in 15% SDS-PAGE. Rabbit polyclonal antibodies anti-HtrE, -NfrA, -YhcD, -GlyA, -Kbl, -PurD, -CRP (1:500 dilution) were used as primary antibodies, which came from our laboratory and validated by corresponding mutants. Horseradish per-
oxidase (HRP)-mouse anti-ribbit IgG (1:3000 dilution, Boson Biotech, Xiamen, China) was used as the secondary antibody. For far-Western blot, recombinant proteins NfrA, HtrE, YhcD on nitrocellulose membrane (NC) membranes were used as bait proteins to capture human serum complement C3b or IgG (1:100 dilution) and then anti-C3b or anti-IgG were used to recognize them, respectively. For Co-IP, beads coupled with C3b antibody (Hycult Biotech Inc., PA, USA) were incubated with a human serum to capture C3b as a bait protein. The bait protein was reacted with recombinant proteins NfrA, HtrE, and YhcD. Recovered pellets were isolated by SDS/PAGE and transferred to NC membranes and then recog-
nized by corresponding antibodies anti- HtrE, -NfrA, or -YhcD. The membranes were developed using electro-chemi-luminescence ECL. Uncropped and unpro-
pcessed scans of all blots are attached in the Source Data file or as supplementary figures in the Supplementary Information.

Detection of O-antigens. Diagnostic sera for Enterotoxigenic Escherichia coli (Cat. TR301, TR302 & TR303) were commercially obtained from Ningbo Tianrun Bio-pharmaceutical Co. LTD, Ningbo, China. O-antigens were detected according to the manufacturer’s instruction. Two lines were drawn on a clean glass slide with a crayon to form two cells. In sterile conditions, one drop of diagnosed serum and sterile saline were added in the first cell as a control and the second cell as a test, respectively. 1 × 10^6 CFU E. coli were mixed in the second cell and then mixed in the first cell until these bacteria were mixed with saline or serum to evenly form an emulsion. The glass slides were gently shaken for 1–2 min and observed with the naked eye. A positive reaction was determined when a milky white agglutination appeared, while a negative reaction resulted from a still emulsion. The results could be confirmed under a low power microscope.

Generation of gene-deletion mutants. Knockout of Y3-glyA, Y1-glyY, Y1-wa-ul, Y3-wa-ul, Y7-wa-ul, Y16-wa-ul, Y12-wa-ul, Y17-wa-ul, Y20-wa-ul, Y23-wa-ul, Y26-wa-ul, Y29-wa-ul, AfnX-Ya-ul, Afbth-Ya-ul, AfpD-kra-ul, AfpB-kra-ul, AspClY-ΔhycDβMtA-ΔhycDβMtA, AfpC-kra-ul, AfpD-kra-ul and AfpE-kra-ul was performed with one-step inactivation of chromosomal genes. For the construction of these mutants,
primers used to clone the kanamycin cassette from pKD13 are listed in Supplementary Table 6. The PCR products were transformed into targeted strains bearing the desired mutations. The PCR products were visualized by agarose gel electrophoresis and were subsequently sequenced.

**Detection of C3b/C3 or C5, and C9 neoantigen.** Fluorescein isothiocyanate (FITC) conjugated monoclonal antibody to human complement factor C3b/C3b (Cat. HM238, clone 3E7) or C9 neoantigen of the terminal complement complex (TCC) (Cat.HM239, clone alll) was from Nycomed, Germany. Anti-C3 Rabbit pAb (Cat. 381678), anti-C5 (N-term) Rabbit pAb (Cat. 616722), and Fluorescein (FITC) aminopurine goat anti-rabbit IgG (Cat.S11011) were from Zenbio, China. For detection of C3b/C3 and C9 neoantigen, 10 μL of cell lysate or serum, diluted 1:100 in PBS buffer, was mixed with 2 μg of FITC-C9 neoantigen monoclonal antibody or 0.5 μg FITC-C9 neoantigen monoclonal antibody for 1 h at 37 °C. For detection of C3 and C5, 10 μL of cell lysate or serum, diluted 1:100 in PBS buffer, was mixed with 2 μg of FITC-C3b/C3 FITC-monoclonal antibody or 0.5 μg FITC-C3b/C3 FITC-monoclonal antibody for 1 h at 37 °C. Unbound primary antibody was removed and then mixed with Fluorescein (FITC) aminopurine goat anti-rabbit IgG at 1:300 for 1 h at 37 °C. Aliquots 1 mL of culture was added into flow tubes and then analyzed on a FACSCalibur flow cytometer. Each sample was observed with forwarding and side scatter and was gated based on forward scatter and side scatter signal. Expression levels were compared among different conditions.

**Isotope tracer experiment.** Stable isotope-labeled compounds were detected by non-targeted detection28, 38. E. coli K21 was cultured using an unlabeled glycan and a 1:1 mixture unlabeled glycan and [U-13C6]-glycine. Three independent biological replicates were performed for each condition. RT-qPCR was performed using an Agilent 7890A GC equipped with an Agilent 5975C MS operating under electron impact (EI) ionization. The effectiveness of each tracer was gauged using the software downloaded from Internet57.

**Protein-small molecular interaction.** MST was carried out as follows28, 35. ATPb, PurR, NfrA, HtrE or YhcD and the N-Dihydroxyurcinamide (NHD) ester fluorescent dye solutions were mixed in a 1:1 ratio and incubated for 30 min at room temperature. The dark and green dyes were visualized by flow cytometry. For the dark dyes, the fluorescence was expressed as the percentage of cells that showed positive signals. For the green dyes, the fluorescence was expressed as the percentage of cells that showed positive signals.

**Electrophoretic mobility shift assay (EMSA).** Purified recombinant PurR and glyA promoter (212 bp) or kb promoter (208 bp) were incubated in the binding buffer (10 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 10 μM DTT, 50% vol/vol glycerol). Electrophoresis was performed in an 8% polyacrylamide (29:1 acrylamide/bisacrylamide) gel, casted in 20 mL Tris–borate, 1 mM EDTA (pH 8.0), 1× (wt/vol) ammonium persulfate, 0.5% (vol/vol) TEMED and run in 20 mL Tris–borate, 1 mM EDTA (pH8.0) at 4 °C at 80 V and stained with a solution of 5 μg/mL ethidium bromide (EB).

**Bacterial clearness in a mouse model.** B6/Nju-Rag1tm1Cgdt/Nju mouse (six weeks), genotype (Rag1)1KO/KO were obtained from Nanjing Biomedical Research Institute of Nanjing University, Nanjing, China. BALB/c mice (8–10 weeks) were obtained from the Experimental Animal Center of Sun Yat-sen University, Guangzhou, China. These animals were acclimatized for one week and randomly divided into the dark and experimental groups (n = 6). The experimental groups were intraperitoneally injected with 10, 15 and 20 mg mg glyR/mouse and control mice were injected with saline (group 0). Blood was withdrawn at 24 h and 48 h for (E. coli dynamic observation), and spleen, kidney, and liver were collected at 24 h after the last injection to spot-plate and to observe CFU. Only those of dilutions yielding 20–200 colonies were enumerated to calculate CFU. During the experiment, no side effects were found in these animals. Animal protocols were approved by the University committee for the use and care of laboratory animals.

**Glycine-potentiated killing by ampicillin in a mouse model.** Six weeks BALB/c mice were obtained from the experimental animal center of Sun Yat-sen University, Guangzhou, China and were acclimatized for one week. These animals were intraperitoneally injected with of glycine (E. coli Y9 (1.5 × 107 CFU), E. coli Y23 (2 × 107 CFU), P. aeruginosa P22 (5 × 107 CFU) or K. pneumoniae 0367 (2 × 107 CFU) per mouse by intravenous injection. The mice were randomly divided into four groups, ten per group and were intraperitoneally injected with saline (group 1), 800 mg kg−1 glycine (group 2), 320 mg kg−1 ampicillin (group 3) and glycine (800 mg kg−1) plus 320 mg kg−1 ampicillin (group 4). The injections were performed at 1 h, 6 h and 48 h post the infection, mouse survival was monitored for fifteen days.

**UPLC-MS/MS to detect glycine in blood and internal organs.** To determine glycine concentration, plasma was drawn from mice and mixed immediately with acetonitrile (1:3, v/v). The mixture was centrifuged twice at 12,000 × g for 10 min, and supernatants were collected. To determine glycine concentrations in liver, kidney, and spleen, these internal organs were removed from 10 untreated mice and 10 treated mice and weighted. These organs were homogenized in acetonitrile (1:2, v/v), Followed by centrifugation twice at 12,000 × g for 10 min, supernatants were collected. The supernatants from both plasma and organs were filtered through a 0.22 μm pore size hydrophilic PVDF membrane. Liquid chromatography was performed at 35 °C using a Waters ACQUITY UPLC system equipped with an Acquity BEH C18 column (50 mm × 2.1 mm i.d., 1.7 μm; Waters Corp.). Separation was using a linear gradient elution with mobile phase A (acetonitrile) and B (0.02% formic acid in ultra-pure water) at a flow rate of 0.2 mL/min. The gradient elution was as follows: 0–3 min, 40% A and 60% B. The injection volume was 3 μL. Mass spectrometry experiments and optimization were carried out with QUATTRO PREMIER XE Triple Quadrupole tandem mass spectrometry (Waters Corp.) with an electrospray ionization source and a source optimization mode (ESI+). The capillary voltage was set to 3000 V; the cone voltage was set to 20 V. The extractor voltage and RF Lens were set at 3 V and 0.5 V, respectively. The desolvation gas flow was set to 650 L/h at a temperature of 450 °C, the cone gas flow rate was set at 50 L/h and the source temperature was set at 120 °C.

**Gene sequencing.** The primers used for amplification are listed in Supplementary Table 7. The deleted genes were amplified by PCR and cloned into the Hind III and BamHI I sites of the pACYC184 (Cat.+) vector or were constructed homologous recombination using pACYC184 (Cat.+) vector. The recombinant plasmids were introduced into DH5α competent cells by electroporation under the condition of 2.5 kV voltage and 6 ms pulse time. The samples were incubated at 37 °C for 45 min and spread onto LB plates containing 50 μg/mL chloramphenicol at 37 °C. Recombinant plasmids were checked by digestion with restriction endonucleases and electroporated into E. coli deletion cells. The acquisition of the deletion mutants utilized a kanamycin-resistant gene to replace these genes by homologous recombination. Thus, these genes and their upstream and downstream of about 200 bp sequences were used for designation of primers. The resulting PCR products were approximately 1700 bp, containing kanamycin-resistant gene sequence (1303 bp), upstream (200 bp) and downstream (200 bp).

**Reverse-transcription qPCR.** Total RNA samples were prepared from indicated tissues using TRIzol reagent (Invitrogen). Double-stranded cDNA was synthesized from total RNA using the SYBR Green real-time series kits (Takara). cDNA was amplification by real-time RT-PCR using an Agilent 2100 Bioanalyzer. Quantitative PCR was performed on each cDNA sample in triplicate. 16s rRNA was used as an internal control to normalize expression levels. Expression level was calculated using the comparative ΔΔCt method. All samples were analyzed in three independent biological replicates with results expressed as the mean ± SEM. The primers used for amplification are listed in Supplementary Table 8.

**PCR and sequencing of K. pneumoniae.** PCR was carried out in a routine procedure. Primers were listed in Supplementary Table 9. 50 μL reaction system contains 2 μL template DNA, 1 μL 10 μM upper or down primer, 2.0 μL 2.5 mM dNTP mix (Takara), 3 μL 10 μL PCR polymerase buffer (TAKARA), 0.5 μL Taq polymerase (TAKARA) and appropriate amount of 4×βL. The PCR programs were applied as following: the denaturation temperature 94 °C for 3 min and 94 °C for 40 s; annealing temperature 56 °C for 30 s; extension at 72 °C for 45 min and spread onto LB plates containing 50 μg/mL chloramphenicol at 37 °C. Recombinant plasmids were checked by digestion with restriction endonucleases and electroporated into E. coli deletion cells. The acquisition of the deletion mutants utilized a kanamycin-resistant gene to replace these genes by homologous recombination. Thus, these genes and their upstream and downstream of about 200 bp sequences were used for designation of primers. The resulting PCR products were approximately 1700 bp, containing kanamycin-resistant gene sequence (1303 bp), upstream (200 bp) and downstream (200 bp).

**Data availability.** All relevant data are available from the authors upon reasonable requests. The source data underlying all Main and Supplementary Figures and Tables are provided as a Source Data file.
25. Peng, B. et al. Exogenous alanine or/and glucose plus kanamycin kills multidrug-resistant bacteria: expression systems and whole-cell biosensors. Appl Microbiol Biotechnol. 100, 4817–4829 (2015).

26. Su, Y. B., Peng, B., Han, Y., Li, H. & Peng, X. X. Fructose restores susceptibility of multidrug-resistant Edwardsiella tarda to kanamycin. J. Proteome Res. 14, 1612–1620 (2015).

27. Peng, B. et al. The pyruvate cycle increases aminoglycosides efficacy and provides respiratory energy in bacteria. Proc. Natl Acad. Sci. USA 115, E1578–E1587 (2018).

28. Yang, J. et al. NaCl promotes antibiotic resistance by reducing redox states in Vibrio alginolyticus. Environ. Microbiol. 20, 4022–4036 (2018).

29. Wang, Z. et al. GC–MS-based metabolome and metabolic regulation in serum-resistant Streplococcus agalactiae. J. Proteome Res. 15, 2246–2253 (2016).

30. Cheng, Z. X. et al. Edwardsiella tarda tunes tricarboxylic acid cycle to evade complement-mediated killing. Front. Immunol. 8, 1706 (2017).

31. Peng, B., Li, H. & Peng, X. X. Functional metabolomics: from biomarker discovery to metabolome reprogramming. Protein Cell 6, 628–637 (2015).

32. Hammes, W., Schleifer, K. H. & Kandler, O. Mode of action of glycine on the biosynthesis of peptidoglycan. J. Bacteriol. 116, 1029–1053 (1973).

33. Wolf, D. & Mascher, T. The applied side of antimicrobial peptide-inducible promoters from Firmicutes bacteria: expression systems and whole-cell biosensors. Appl Microbiol Biotechnol. 100, 4817–4829 (2015).

34. Moruth, K. H. et al. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104, 301–311 (2001).

35. Chonn, A., Cullis, P. R. & Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146, 4234–4241 (1991).

36. Richards, R. L., Gewurz, H., Osmand, A. P. & Alving, C. R. Interactions of C-reactive protein and complement with liposomes. Proc. Natl Acad. Sci. USA 74, 5672–5676 (1977).

37. Hiller, K., Metallo, C. & Stephanopoulos, G. Elucidation of cellular metabolism via metabolomics and stable-isotope assisted metabolomics. Curr. Pharm. Biotechnol. 12, 1075–1086 (2011).

38. Walther, J. L., Metallo, C. M., Zhang, J. & Stephanopoulos, G. Optimization of 13C isotopic tracers for metabolic flux analysis in mammalian cells. Metab. Eng. 14, 162–171 (2012).

39. Bennett, B. D. et al. Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. Nat. Chem. Biol. 5, 593–599 (2009).

40. Wilson, R. L., Stauffer, L. T. & Stauffer, G. V. Roles of the GcvA and PurR transcription factors and global physiology of the cell. J. Immunol. 185, 1815–1822 (2009).

41. Phan, M. D. et al. The serum resistance of globally disseminated multidrug resistant uropathogenic Escherichia coli clone. MBio 8, e00603-17 (2017).

42. Tieng et al. Nlp facilitates deposition of Cbp on Escherichia coli by blocking classical complement-mediated killing, which results in high-level bacteremia. Infect. Immun. 80, 3669–3678 (2012).

43. Lindholm, M., Aung, K. M., Wai, S. N. & Oscarsson, J. Role of OmpA1 and OmpA2 in Aggregatibacter actinomycetemcomitans and Aggregatibacter aphrophilus serum resistance. J. Oral. Microbiol. 11, 1536192 (2017).

44. Prasadarao, N. V., Blom, A. M., Villoutreix, B. O. & Linsangan, L. C. A novel interaction of outer membrane protein A with Cbp binding protein mediates serum resistance of Escherichia coli K1. J. Immunol. 169, 6352–6360 (2002).

45. Wooster, D. G., Maruvada, R., Blom, A. M. & Prasadarao, N. V. Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting Cbp-mediated Csb and Cbp degradation. Immunology 117, 482–493 (2006).

46. Liu, Y. F. et al. Loss of outer membrane protein C in Escherichia coli contributes to both antibacterial resistance and escaping antibody-dependent bactericidal activity. Infect. Immun. 80, 1815–1822 (2012).

47. Phan, M. D. et al. The serum resistance of globally disseminated multidrug resistant uropathogenic Escherichia coli clone. MBio 8, e00603-17 (2017).

48. Cremer, L. et al. Innate immune evasion of Escherichia coli clinical strains from orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis. 35, 993–999 (2016).

49. Coggon, C. F. et al. A novel method of serum resistance by Escherichia coli that causes urosepsis. MBio 9, e00920–18 (2018).

50. Wells, T. J. et al. Increased severity of respiratory infections associated with elevated anti-LPS IgG2 which inhibits serum bactericidal killing. J. Exp. Med. 211, 1893–1904 (2014).

51. Huja, S. et al. Fur is the master regulator of the extraintestinal pathological Escherichia coli response to serum. MBio 5, e01460–14 (2014).

52. Hu, Y. H. & Sun, L. The global regulatory effect of Edwardsiella tarda Fur on iron acquisition, stress resistance, and host infection: a proteomics-based investigation. J. Proteome Res. 14, 100–110 (2015).

53. Cohen, M. S. & Cooney, M. H. A bacterial respiratory burst: stimulation of the metabolism of Nessleria gonorrhoeae by human serum. J. Infect. Dis. 150, 49–56 (1984).

54. Dankert, J. R. Complement-mediated inhibition of function in complement-resistant Escherichia coli. J. Immunol. 142, 1391–1395 (1989).

55. Peng, B. et al. Exogenous alanine or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 21, 249–261 (2015).

56. Su, Y. B., Peng, B., Han, Y., Li, H. & Peng, X. X. Fructose restores susceptibility of multidrug-resistant Edwardsiella tarda to kanamycin. J. Proteome Res. 14, 1612–1620 (2015).

57. Peng, B. et al. The pyruvate cycle increases aminoglycosides efficacy and provides respiratory energy in bacteria. Proc. Natl Acad. Sci. USA 115, E1578–E1587 (2018).
57. Hiller, K. et al. NTFTD—a stand-alone application for the non-targeted detection of stable isotope-labeled compounds in GC/MS data. *Bioinformatics* **29**, 1226–1228 (2013).
58. Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D. & Duhr, S. Protein-binding assays in biological liquids using microscale thermophoresis. *Nat. Commun.* **1**, 100 (2010).
59. Jiang, M. et al. Phenylalanine enhances innate immune response to clear ceftazidime-resistant *Vibrio alginolyticus* in *Danio rerio*. *Fish. Shellfish Immunol.* **84**, 912–919 (2019).

**Acknowledgements**

This work was sponsored by grants from the National Key Research and Development Program of China (2018YFD0900501/4), NSFC projects (U1701235, 31822058, 31770045, 41276145), and The Blue Life Breakthrough Program of LMBB for Pilot National Laboratory, Marine Science and Technology (Qingdao), China (MS2018NO06).

**Author contributions**

X.X.P., B.P. and H.L. wrote the manuscript. X.X.P., B.P., H.L. and T.T.Z. conceptualized and designed the project. Z.G.C., X.X.P., T.T.Z., B.P., H.L., Z.X.C., C.G., T.C.Y. and J.Y.Z. interpreted the data. C.G., Z.G.C., J.Y.Z., T.T.Z., T.C.Y. and J.X.Z. performed data analysis and collected samples. Z.X.C., H.L., J.W. and D.L. performed experiments.

**Additional information**

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-019-11129-5.

**Competing interests:** The authors declare no competing interests.

**Reprints and permission** information is available online at http://npg.nature.com/reprintsandpermissions/

**Peer review information:** Nature Communications thanks Jim Cassat and Timothy Wells for their contribution to the peer review of this work. Peer reviewer reports are available.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

© The Author(s) 2019